[HTML][HTML] Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman, A Millier… - PLoS …, 2020 - journals.plos.org
Objective The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
[HTML][HTML] Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman, A Millier… - PLoS ONE, 2020 - ncbi.nlm.nih.gov
Objective The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman… - PLOS …, 2020 - econpapers.repec.org
Objective: The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
K Bowrin, JB Briere, L Fauchier, C Coleman… - PLoS …, 2020 - search.ebscohost.com
Objective: The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman, A Millier… - PLOS ONE, 2020 - ideas.repec.org
Objective: The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
[引用][C] Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman, A Millier… - PLoS ONE, 2020 - hal.science
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the
context of stroke prevention in atrial fibrillation in France - Archive ouverte HAL Accéder …
context of stroke prevention in atrial fibrillation in France - Archive ouverte HAL Accéder …
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman… - PloS …, 2020 - pubmed.ncbi.nlm.nih.gov
Objective The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
K Bowrin, JB Briere, L Fauchier, C Coleman, A Millier… - Plos one, 2020 - europepmc.org
OBJECTIVE: The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
[PDF][PDF] Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman… - PLoS ONE, 2020 - scholar.archive.org
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the
context of stroke prevention in atrial f Page 1 RESEARCH ARTICLE Real-world cost-effectiveness …
context of stroke prevention in atrial f Page 1 RESEARCH ARTICLE Real-world cost-effectiveness …
[引用][C] Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman… - PLoS …, 2020 - ui.adsabs.harvard.edu
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the
context of stroke prevention in atrial fibrillation in France - NASA/ADS Now on home page ads …
context of stroke prevention in atrial fibrillation in France - NASA/ADS Now on home page ads …